| Neil Kumar |
Neil Kumar is the founder of BridgeBio Pharma LLC, founded in 2015, where he holds the title of Chief Executive Officer & Director. He is also the founder of BridgeBio Pharma, Inc., founded in 2015, where he holds the title of Chief Executive Officer & Director. Dr. Kumar's current job(s) include being the Chief Executive Officer at Eidos Therapeutics, Inc. since 2016, President & Chief Executive Officer at BridgeBio Services, Inc., Director at PellePharm, Inc., Director at Navire Pharma, Inc., Director at LianBio since 2019, and President at QED Therapeutics, Inc., Origin Biosciences, Inc., Phoenix Tissue Repair, Inc., Adrenas Therapeutics, Inc., Calcilytix Therapeutics, Inc., and BridgeBio Chemistry, Inc. Dr. Kumar's former job(s) include being the Vice President-Business Development at MyoKardia, Inc. from 2012 to 2014, Associate Principal at McKinsey & Co., Inc. from 2007 to 2011, and Principal at Third Rock Ventures LLC. Dr. Kumar has an educational background with an undergraduate degree and a graduate degree from Stanford University, as well as a doctorate degree from Massachusetts Institute of Technology. |
| Matthew Outten |
Matthew Outten is currently the Chief Commercial Officer at QED Therapeutics, Inc. and also holds the position of Chief Commercial Officer at BridgeBio Pharma, Inc. He previously worked as the Vice President-Marketing & Marketing Access at Pharmacyclics LLC from 2013 to 2018. Outten completed his undergraduate degree at Hamilton College (New York) and earned an MBA from the University of Delaware. |
| Thomas Trimarchi |
Thomas Trimarchi is currently the Director at ML Bio Solutions, Inc. and the Chief Product Officer at BridgeBio Pharma, Inc. He previously worked as a Principal at Truist Securities, Inc. in 2015. He also worked as an Analyst at Goldman Sachs & Co. LLC. From 2006 to 2008, he was a Research Associate at the University of Vermont. Trimarchi received his undergraduate degree from the University of Vermont in 2006 and his doctorate from New York University School of Medicine in 2015. |
| Eric Michael David |
Eric Michael David is the founder of Organovo, Inc. which was founded in 2007. He held the title of Chief Strategy Officer. Currently, he is the Chief Executive Officer-Gene Therapy at BridgeBio Pharma, Inc. and a Member at New York State Bar Association. In the past, he held the position of Chief Strategy Officer & Executive Vice President at Organovo Holdings, Inc. from 2012 to 2017. Prior to that, he was an Associate Partner at McKinsey & Co., Inc. from 2005 to 2012 and an Assistant Professor at The Rogosin Institute, Inc. He received his undergraduate degree from Amherst College, his graduate degree from Columbia Law School, and his doctorate from Columbia University College of Physicians & Surgeons. |
| Uma Sinha |
Uma Sinha is an Independent Director at ProKidney Corp. She is also currently serving as the Chief Scientific Officer at Eidos Therapeutics, Inc. since 2021 and at BridgeBio Pharma, Inc. since 2016. Previously, she held positions such as Senior Director-Cardiovascular at Millennium Pharmaceuticals, Inc., Independent Director at Social Capital Suvretta Holdings Corp. III, Principal at COR Therapeutics, Inc., Principal at Genencor International, Inc., Vice President & Head-Biology at Portola Pharmaceuticals LLC, and Chief Scientific Officer at Global Blood Therapeutics, Inc. from 2014 to 2015. Dr. Sinha holds a doctorate degree from the University of Georgia and an undergraduate degree from Presidency College. |
| Christine E. Siu |
Christine E. Siu currently works at Vividion Therapeutics, Inc., as Director from 2021, Bright Peak Therapeutics AG, as Independent Director from 2021, Monte Rosa Therapeutics, Inc., as Independent Director from 2020, Bright Peak Therapeutics, Inc., as Director, and BridgeBio Pharma, Inc., as Chief Operating Officer from 2020. Ms. Siu also formerly worked at NeuroTherapeutics Pharma, Inc., as Director, Global Blood Therapeutics, Inc., as Senior Director-Corporate Development from 2012 to 2014, Bear, Stearns & Co., Inc., as Analyst, Warburg Pincus LLC, as Portfolio Manager, Thomas, McNerney & Partners LLC, as Vice President from 2005 to 2010, Third Rock Ventures LLC, as Principal, The Bluefield Project to Cure Frontotemporal Dementia, as Chief Business Officer from 2014 to 2017, and Eidos Therapeutics, Inc., as Chief Financial Officer from 2017 to 2019. Ms. Siu received her undergraduate degree from the University of Michigan and Masters Business Admin degree from Harvard Business School. |
| Brian C. Stephenson |
Brian C. Stephenson is currently the Chief Financial Officer at BridgeBio Pharma, Inc. Prior to his current position, he held the role of Director & Vice President at Leerink Partners LLC from 2011 to 2014. From 2007 to 2011, he worked as an Engagement Manager at McKinsey & Co., Inc. Additionally, he served as a Partner & Head-Life Sciences at Capital IP Investment Partners LLC from 2015 to 2018. Dr. Stephenson obtained his undergraduate degree from Brigham Young University and pursued graduate and doctorate degrees at the Massachusetts Institute of Technology AgeLab. |
| Francis Patrick McCormick |
Francis Patrick McCormick is the founder of BridgeBio Pharma LLC (founded in 2015), Onyx Pharmaceuticals, Inc. (founded in 1992), Avidity Biosciences, Inc. (founded in 2012), and BridgeBio Pharma, Inc. (founded in 2015). He held the title of Chief Scientific Officer at Onyx Pharmaceuticals, Inc. from 1992 to 1996. He is currently a Director at PellePharm, Inc., Arresto BioSciences, Inc., Melanoma Therapeutics Foundation, UCSF Helen Diller Family Comprehensive Cancer Center, Navire Pharma, Inc., and a Member of the National Academy of Sciences since 2014. Dr. McCormick is also the founder of DNAtrix, Inc. He has held former positions as an Independent Director at Exelixis, Inc. from 2003 to 2014, Aduro BioTech, Inc. from 2010 to 2019, Olema Pharmaceuticals, Inc. from 2014 to 2021, and as Vice President-Research at Chiron Corp. from 1991 to 1992. He was also Vice President-Discovery Research at Cetus Corp. from 1981 to 1992. He served as President of the American Association for Cancer Research in 2013 and was an Associate Dean at UCSF School of Medicine from 1997 to 2014. Dr. McCormick received a doctorate degree from the University of Cambridge in 1975 and an undergraduate degree from the University of Birmingham in 1972. |
| Adora Ndu |
Adora Ndu is currently the Director at ACADIA Pharmaceuticals, Inc., the Independent Director at DBV Technologies SA, the Director at Alliance for Regenerative Medicine, and the Chief Regulatory & Legal Officer at BridgeBio Pharma, Inc. Previously, she worked as the Director-Medical Policy Development at the US Food & Drug Administration from 2008 to 2016. She also served as the VP-World Wide Research & Development at BioMarin Pharmaceutical, Inc. from 2017 to 2022. Additionally, she was a Member at the University of Maryland from 2016 to 2019. Dr. Ndu holds a graduate degree from The University of Maryland Francis King Carey School of Law and a doctorate degree from Howard University College of Medicine. |
| Richard H. Scheller |
Richard H. Scheller is currently the Director and Chairman-Research & Development at BridgeBio Pharma LLC and the Chairman-Research & Development at BridgeBio Pharma, Inc. He is also the Chairman at DICE Molecules SV, Inc., the Director at DiCE Molecules, Inc., and the Director at 23andMe, Inc. Additionally, he serves as an Independent Director at Alector, Inc., Maze Therapeutics, Inc., 23andMe Holding Co., and Aarvik Therapeutics, Inc. Dr. Scheller is a Trustee at the California Institute of Technology and the Fine Arts Museums of San Francisco. He is a Member of the National Academy of Sciences, the American Academy of Arts & Sciences, and the National Academy of Medicine (United States). Furthermore, he holds the position of Science Partner at The Column Group LLC and Advisor at GV Management Co. LLC. Formerly, Dr. Scheller served as the Chairman at DICE Therapeutics, Inc. from 2015 to 2023. He was also a Director at Cornerstone Pharmaceuticals, Inc., Medrio, Inc., Xenon Pharmaceuticals, Inc., Oric Pharmaceuticals, Inc., and Affinita Biotech, Inc. Prior to that, he held the position of Executive VP, Head-Research & Early Development at Genentech, Inc. from 2001 to 2015 and Head-Genentech Research & Early Development at Roche Holding AG from 2009 to 2014. He was a Professor at Stanford University from 1982 to 1994. Dr. Scheller obtained a doctorate degree from The Trustees of Columbia University in The City of New York and California Institute of Technology in 1980. He also holds an undergraduate degree from the University of Wisconsin. |
| Jonathan C. Fox |
Jonathan C. Fox is currently serving as an Independent Director at Edgewise Therapeutics, Inc., a Director at ML Bio Solutions, Inc., and a Trustee at Lankenau Institute for Medical Research. He is also the President & Chief Medical Officer at Eidos Therapeutics, Inc. and BridgeBio Pharma, Inc. Previously, he held positions as a Senior Director-Clinical Cardiovascular Research at Merck & Co., Inc., a Director-Clinical Pharmacology at GlaxoSmithKline LLC, and the Chief Medical Officer at MyoKardia, Inc. from 2013 to 2016. He has also worked as a Consulting Professor at Stanford University, a Clinical Professor at the University of Pennsylvania, and a Consultant at The University of California, San Francisco. Additionally, he served as the Vice President-Clinical Development at AstraZeneca LP from 2004 to 2012. Dr. Fox obtained his undergraduate and doctorate degrees from The University of Chicago. |
| Hannah A. Valantine |
Hannah A. Valantine is the founder of Hav LLC, a company founded in 2021 where she holds the title of Principal. She is currently working as an Independent Director at CareDx, Inc., Pacific Biosciences of California, Inc., and BridgeBio Pharma, Inc., all since 2021. Additionally, she is a Professor at Stanford University School of Medicine since 1987 and a Member of the National Academy of Medicine (United States). Dr. Valantine completed her undergraduate and doctorate degrees at the University of London and also holds an undergraduate degree from Chelsea College. |
| Fred Hassan |
Fred Hassan is the founder of Caret Pharma LLC (2017) and IM HealthScience LLC (2010), where he serves as Chairman. Mr. Hassan is also the founder of Caret Group LLC. Currently, Mr. Hassan holds the position of Chairman at Saghmos Therapeutics, Inc. (since 2023), Non-Executive Chairman at Physician's Seal LLC, Managing Director at Warburg Pincus LLC (since 2011), Independent Director at Precigen, Inc. (since 2016), Independent Director at Cocrystal Pharma, Inc. (since 2023), Independent Director at BridgeBio Pharma, Inc. (since 2021), Member of The Business Council, and Advisor at Caerus Ventures LLC. Mr. Hassan's former positions include Chairman, President & Chief Executive Officer at Merck & Co., Inc. (2003-2009), President & Chief Executive Officer at Pharmacia & Upjohn, Inc. (1997-2000), Chairman & Chief Executive Officer at Schering-Plough Corp. (2003-2009), Chairman & Chief Executive Officer at Pharmacia Corp. (2000-2003), Non-Executive Chairman at Avon Products, Inc. (1999-2013), Non-Executive Chairman at Bausch & Lomb, Inc. (2010-2013), Chairman of Pharmaceutical Research & Manufacturers of America, Chairman of Theramex HQ UK Ltd., Director & Executive Vice President at Wyeth LLC (1993-1997), Independent Director at Amgen, Inc. (2015-2021), Director at Electronic Data Systems Corp., Independent Director at Time Warner, Inc. (2009-2018), Director at Bausch Health Cos., Inc. (2013-2014), Independent Director at Prometheus Biosciences, Inc. (2021-2023), President of International Federation of Pharmaceutical Manufacturers, and President at Wyeth-Ayerst Laboratories (1989-1993). Mr. Hassan's education includes an undergraduate degree from Imperial College London and an MBA from Harvard Business School. |
| Randal W. Scott |
Randal W. Scott was the founder of Genomic Health, Inc. (founded in 2000) where he served as the Executive Chairman from 2009 to 2012. He is also the founder of Invitae Corp. (founded in 2010) where he currently holds the position of Executive Chairman. Additionally, he is the founder of Genome Medical, Inc. (founded in 2016) where he currently serves as the Chairman. Dr. Scott's current job(s) include being the Executive Co-Chairman at Genomic Life, Inc. since 2021, a Director at Freenome Holdings, Inc. since 2017, an Independent Director at Talis Biomedical Corp. since 2014, and an Independent Director at BridgeBio Pharma, Inc. since 2020. Dr. Scott's former job(s) include being the Chairman of Invitae Corp., a Director at Station X, Inc., and the President of Incyte Pharmaceuticals, Inc.Dr. Scott's education history includes an undergraduate degree from Emporia State University and a doctorate degree from the University of Kansas. |
| Douglas Adam Dachille |
Douglas Adam Dachille is the founder of First Principles Capital Management LLC, which was founded in 2003. He is currently a Director at Lyndra Therapeutics, Inc. and a Director and Independent Director at BridgeBio Pharma LLC and BridgeBio Pharma, Inc., respectively. He previously worked as a Managing Director at JPMorgan Securities LLC, Chief Investment Officer & Executive VP at American International Group, Inc., Co-Treasurer & Head-Global Proprietary Trading at JPMorgan Chase & Co., President & Chief Operating Officer at Zurich Capital Markets, Inc., and Chief Operating Officer at Zurich Financial Services Ltd. Mr. Dachille holds an MBA from The University of Chicago, an undergraduate degree from Union University, and an undergraduate degree from Albany Medical College. |
| Ali J. Satvat |
Ali J. Satvat is currently a Director at AcuFocus, Inc., Arbor Pharmaceuticals LLC, Ipi Legacy Liquidation Co., Coherus BioSciences, Inc., Clarify Health Solutions, Inc., Slayback Pharma LLC, BridgeBio Pharma LLC, Trilogy Medwaste, Inc., Blue Sprig Pediatrics, Inc., BridgeBio Pharma, Inc., Headlands Research, Inc., BioCrucible Ltd., Sapphiros, KKR Management LLC, and Kohlberg Kravis Roberts & Co. LP. He previously worked as a Director at PRA Health Sciences, Inc., Cognizant TriZetto Software Group, Inc., Cohera Medical, Inc., Chiron Holdings Pte Ltd., TZ Holdings LP, and Healthcare Private Equity Association. He was also an Independent Director at Eidos Therapeutics, Inc. and a Principal at Apax Partners, Inc., Johnson & Johnson Innovation - JJDC, Inc., The Blackstone Group, Inc. (Illinois), and Audax Management Co. (NY) LLC. Mr. Satvat holds an MBA from The Wharton School of the University of Pennsylvania and an undergraduate degree from Harvard College. |
| Eric I. Aguiar |
Eric I. Aguiar is currently the Lead Independent Director at Invitae Corp., the Director at BridgeBio Pharma LLC, the Independent Director at BridgeBio Pharma, Inc., the Lead Independent Director at Biomea Fusion, Inc., the Director at Garuda Therapeutics, Inc., and a Partner at Aisling Capital LLC. He is also a Member of the Council on Foreign Relations, Inc. and a Council Member at Tufts University School of Medicine. In the past, Dr. Aguiar served as the Chief Executive Officer & Director at Genovo, Inc., the Executive Director at TheraTech, Inc., the Non-Executive Director at Amarin Corp. Plc, and a Director at 3-Dimensional Pharmaceuticals, Inc., Oriel Therapeutics, Inc., CardioKine, Inc., SkinMedica, Inc., Virdante Pharmaceuticals, Inc., Amarin Pharmaceuticals, Inc., Metaphore Pharmaceuticals, Inc., VaxInnate Corp., Intuity Medical, Inc., and Locus Development, Inc. He was also a Managing Director at HealthCare Ventures LLC, the Vice President & Managing Director at Philadelphia Ventures, Inc., and a Partner at Thomas, McNerney & Partners LLC. Dr. Aguiar received his undergraduate degree from Cornell University and his doctorate from Harvard Medical School. |
| Andrew W. Lo |
Andrew W. Lo is the founder of Quantile Health Inc (2021), AlphaSimplex Group LLC (1999), BridgeBio Pharma, Inc. (2015), and QLS Advisors LLC (2019). He currently holds positions as Director-Laboratory for Financial Engineering at Massachusetts Institute of Technology, Independent Director at AbCellera Biologics, Inc. (2021 - present), Director at Atomwise, Inc. (2021 - present), Director at Annual Reviews, and Research Associate at National Bureau of Economic Research, Inc. He is also a Professor at MIT Sloan School of Management (1988 - present). Dr. Lo has previously held positions as Director at Crown Bioscience, Inc., Independent Director at Roivant Sciences Ltd. (2016 - 2022), Director at Whitehead Institute for Biomedical Research, and Independent Director at Montes Archimedes Acquisition Corp. Dr. Lo received his doctorate degree from Harvard University in 1984 and his undergraduate degree from Yale University in 1980. |
| Ronald J. Daniels |
Ronald J. Daniels is currently serving as a Director at Computershare Investor Services LLC and Greater Baltimore Committee. He is also an Independent Director at BridgeBio Pharma, Inc. and T. Rowe Price Exchange-Traded Funds, Inc. Additionally, he is a Trustee at Johns Hopkins Medicine, Inc. and a Member-Governors Board at Teachers Insurance & Annuity Association of America. Previously, he served as a Director at Moore Wallace, Inc., CanWest Global Communications Corp., Great Lakes Power, Inc., Rockwater Capital Corp., and Biohealth Innovation, Inc. He was also the Chief Investment Officer & Executive VP at American International Group, Inc. from 2015 to 2021. He has also worked as a Professor at the University of Pennsylvania. Mr. Daniels received his graduate degree from Yale University in 1988 and his undergraduate degree from the University of Toronto in 1982. |
| Andrea J. Ellis |
Andrea J. Ellis is currently working as an Independent Director at BridgeBio Pharma, Inc., as the Chief Financial Officer at Neutron Holdings, Inc., and as the Chief Financial Officer at The Lime Truck LLC. Ms. Ellis has an undergraduate degree from the University of Pennsylvania and an MBA from Harvard Business School. |
